Cargando…
Use of oral hydromorphone in a patient with stage D heart failure
Patients with advanced heart failure often experience dyspnea, fatigue, edema, and appetite loss. If these symptoms are refractory to treatment, palliative care via a team approach is necessary. We describe a patient with stage D heart failure whose dyspnea and overall condition improved with compre...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8326605/ https://www.ncbi.nlm.nih.gov/pubmed/34377492 http://dx.doi.org/10.1177/2050313X211037445 |
_version_ | 1783731862653370368 |
---|---|
author | Nakamura, Tomohiro Nakamura, Mari Shibasaki, Yumiko Mizukami, Sachie Tomita, Haruki Hirai, Masaru Matsumoto, Mitsunari Ishida, Takeshi Momomura, Shin-ichi |
author_facet | Nakamura, Tomohiro Nakamura, Mari Shibasaki, Yumiko Mizukami, Sachie Tomita, Haruki Hirai, Masaru Matsumoto, Mitsunari Ishida, Takeshi Momomura, Shin-ichi |
author_sort | Nakamura, Tomohiro |
collection | PubMed |
description | Patients with advanced heart failure often experience dyspnea, fatigue, edema, and appetite loss. If these symptoms are refractory to treatment, palliative care via a team approach is necessary. We describe a patient with stage D heart failure whose dyspnea and overall condition improved with comprehensive medical treatments including conventional medications for heart failure, continuous infusions of catecholamine and diuretic, and oral hydromorphone. A 67-year-old man with a 12-year history of dilated cardiomyopathy was admitted to our hospital due to exacerbation of heart failure. Despite continuous infusion of catecholamine and diuretic, his dyspnea and liver and renal function continued to worsen. Oral hydromorphone was administered to relieve his refractory dyspnea, which also improved his conditions, continuous infusion of the catecholamine and diuretic could withdraw. Oral low-dose hydromorphone used in the present case might be a helpful agent for treating dyspnea in stage D heart failure patients with renal dysfunction. |
format | Online Article Text |
id | pubmed-8326605 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | SAGE Publications |
record_format | MEDLINE/PubMed |
spelling | pubmed-83266052021-08-09 Use of oral hydromorphone in a patient with stage D heart failure Nakamura, Tomohiro Nakamura, Mari Shibasaki, Yumiko Mizukami, Sachie Tomita, Haruki Hirai, Masaru Matsumoto, Mitsunari Ishida, Takeshi Momomura, Shin-ichi SAGE Open Med Case Rep Case Report Patients with advanced heart failure often experience dyspnea, fatigue, edema, and appetite loss. If these symptoms are refractory to treatment, palliative care via a team approach is necessary. We describe a patient with stage D heart failure whose dyspnea and overall condition improved with comprehensive medical treatments including conventional medications for heart failure, continuous infusions of catecholamine and diuretic, and oral hydromorphone. A 67-year-old man with a 12-year history of dilated cardiomyopathy was admitted to our hospital due to exacerbation of heart failure. Despite continuous infusion of catecholamine and diuretic, his dyspnea and liver and renal function continued to worsen. Oral hydromorphone was administered to relieve his refractory dyspnea, which also improved his conditions, continuous infusion of the catecholamine and diuretic could withdraw. Oral low-dose hydromorphone used in the present case might be a helpful agent for treating dyspnea in stage D heart failure patients with renal dysfunction. SAGE Publications 2021-07-31 /pmc/articles/PMC8326605/ /pubmed/34377492 http://dx.doi.org/10.1177/2050313X211037445 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by-nc/4.0/This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access page (https://us.sagepub.com/en-us/nam/open-access-at-sage). |
spellingShingle | Case Report Nakamura, Tomohiro Nakamura, Mari Shibasaki, Yumiko Mizukami, Sachie Tomita, Haruki Hirai, Masaru Matsumoto, Mitsunari Ishida, Takeshi Momomura, Shin-ichi Use of oral hydromorphone in a patient with stage D heart failure |
title | Use of oral hydromorphone in a patient with stage D heart failure |
title_full | Use of oral hydromorphone in a patient with stage D heart failure |
title_fullStr | Use of oral hydromorphone in a patient with stage D heart failure |
title_full_unstemmed | Use of oral hydromorphone in a patient with stage D heart failure |
title_short | Use of oral hydromorphone in a patient with stage D heart failure |
title_sort | use of oral hydromorphone in a patient with stage d heart failure |
topic | Case Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8326605/ https://www.ncbi.nlm.nih.gov/pubmed/34377492 http://dx.doi.org/10.1177/2050313X211037445 |
work_keys_str_mv | AT nakamuratomohiro useoforalhydromorphoneinapatientwithstagedheartfailure AT nakamuramari useoforalhydromorphoneinapatientwithstagedheartfailure AT shibasakiyumiko useoforalhydromorphoneinapatientwithstagedheartfailure AT mizukamisachie useoforalhydromorphoneinapatientwithstagedheartfailure AT tomitaharuki useoforalhydromorphoneinapatientwithstagedheartfailure AT hiraimasaru useoforalhydromorphoneinapatientwithstagedheartfailure AT matsumotomitsunari useoforalhydromorphoneinapatientwithstagedheartfailure AT ishidatakeshi useoforalhydromorphoneinapatientwithstagedheartfailure AT momomurashinichi useoforalhydromorphoneinapatientwithstagedheartfailure |